SCHEMBL6779050

SCHEMBL6779050

NN=CNc1cccc(C(=O)NCC(=O)NC(CC(=O)O)c2cccc(OCC(=O)O)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 7/20 0.46
ITGB3 P05106 9/20 0.44
ITGAV P06756 7/20 0.44
ITGB1 P05556 6/20 0.44
ITGA5 P08648 6/20 0.44
ITGB5 P18084 2/20 0.44
ITGB6 P18564 2/20 0.44
ITGB8 P26012 2/20 0.44
ITGA8 P53708 2/20 0.44
MDM4 O15151 2/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
MDM2 Q00987 3/20 0.43
ITGA2B P08514 2/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6782755 0.90 ITGB3 (0.51) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL6778594 0.88 ITGB3 (0.48) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL6780575 0.88 ITGB3 (0.45) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL7343510 0.88 GPR139 (0.51) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL7340220 0.87 ITGB3 (0.46) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL7341209 0.87 GPR139 (0.52) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL7836882 0.86 ITGB3 (0.48) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL6779037 0.86 MAPK1 (0.48) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL6777818 0.86 ITGB3 (0.45) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL7833841 0.85 ITGB3 (0.49) GPR139ITGB3ITGAVITGB1ITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed